{"id":"W2909116479","doi":"10.1182/blood-2018-99-118362","title":"Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Venetoclax; Obinutuzumab; Bendamustine; Chronic lymphocytic leukemia; Rituximab; Medicine; Ofatumumab; Ven; Internal medicine; Leukemia; Ibrutinib; Fludarabine; Oncology; Immunology; Lymphoma; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001302627,0.0005588069,0.001082191,0.0003578192,0.0002551869,0.0007671107,0.000559978,0.0006909434,0.001324143],"category_scores_gemma":[0.0008857602,0.0003419697,0.0007019723,0.0002869569,0.0005965682,0.0005725226,0.0002539495,0.001656397,0.0003209995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006315702,"about_ca_system_score_gemma":0.0007207944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005018665,"about_ca_topic_score_gemma":0.001556722,"domain_scores_codex":[0.9994817,0.0003150984,0.00002580535,0.00007055985,0.00003920437,0.0000676283],"domain_scores_gemma":[0.9993654,0.0001650417,0.0001592226,0.00004006279,0.00001968661,0.0002506335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.653969,0.04450595,0.02418085,0.0006649605,0.001265786,0.0003278003,0.00042852,0.003593851,0.07071022,0.0002434198,0.002060973,0.1980486],"study_design_scores_gemma":[0.1455799,0.8077049,0.03563672,0.00006032583,0.000638023,0.0004185135,0.00006868459,0.001459003,0.005971791,0.0001597385,0.00226982,0.00003261269],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978223,0.001170949,0.0001169544,0.00009167346,0.00002029462,0.0001515629,0.0001686281,0.00001898599,0.0004386015],"genre_scores_gemma":[0.9978625,0.0006291012,0.0003196989,0.0001267877,0.00006435314,0.0001786045,0.0003506835,0.000006697104,0.0004615321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001324143,"threshold_uncertainty_score":0.006889045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01441151392181346,"score_gpt":0.2837384014800938,"score_spread":0.2693268875582804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}